CL2021002241A1 - Proteínas de unión condicionalmente activadas restringidas (divisional de la solicitud no. 202000570) - Google Patents

Proteínas de unión condicionalmente activadas restringidas (divisional de la solicitud no. 202000570)

Info

Publication number
CL2021002241A1
CL2021002241A1 CL2021002241A CL2021002241A CL2021002241A1 CL 2021002241 A1 CL2021002241 A1 CL 2021002241A1 CL 2021002241 A CL2021002241 A CL 2021002241A CL 2021002241 A CL2021002241 A CL 2021002241A CL 2021002241 A1 CL2021002241 A1 CL 2021002241A1
Authority
CL
Chile
Prior art keywords
split
restricted
application
binding proteins
activated binding
Prior art date
Application number
CL2021002241A
Other languages
English (en)
Inventor
Anand Panchal
Chad May
Robert B Dubridge
Maia Vinogradova
Original Assignee
Maverick Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maverick Therapeutics Inc filed Critical Maverick Therapeutics Inc
Publication of CL2021002241A1 publication Critical patent/CL2021002241A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se refiere a construcciones de activación redirigidas biespecíficas convencionales, o COBRA, que se administran en un formato profármaco activo. Tras la exposición a las proteasas tumorales, las construcciones se escinden y activan, de modo que pueden unirse tanto a los antígenos objetivo tumorales (TTA) como a CD3, reclutando así las células T que expresan CD3 al tumor, lo que da como resultado el tratamiento.
CL2021002241A 2017-09-08 2021-08-25 Proteínas de unión condicionalmente activadas restringidas (divisional de la solicitud no. 202000570) CL2021002241A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762555943P 2017-09-08 2017-09-08
US201762586627P 2017-11-15 2017-11-15
US201762587318P 2017-11-16 2017-11-16

Publications (1)

Publication Number Publication Date
CL2021002241A1 true CL2021002241A1 (es) 2022-04-29

Family

ID=63788010

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2020000570A CL2020000570A1 (es) 2017-09-08 2020-03-06 Proteínas de unión condicionalmente activadas restringidas
CL2021002241A CL2021002241A1 (es) 2017-09-08 2021-08-25 Proteínas de unión condicionalmente activadas restringidas (divisional de la solicitud no. 202000570)
CL2021002242A CL2021002242A1 (es) 2017-09-08 2021-08-25 Proteínas de unión condicionalmente activadas restringidas (divisional de la solicitud no. 202000570)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2020000570A CL2020000570A1 (es) 2017-09-08 2020-03-06 Proteínas de unión condicionalmente activadas restringidas

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2021002242A CL2021002242A1 (es) 2017-09-08 2021-08-25 Proteínas de unión condicionalmente activadas restringidas (divisional de la solicitud no. 202000570)

Country Status (18)

Country Link
US (5) US11406710B2 (es)
EP (1) EP3679067A2 (es)
JP (2) JP7268005B2 (es)
KR (1) KR20200047687A (es)
CN (1) CN111356700A (es)
AU (3) AU2018328291B2 (es)
BR (1) BR112020004543A2 (es)
CA (1) CA3075034A1 (es)
CL (3) CL2020000570A1 (es)
EC (1) ECSP20021323A (es)
IL (3) IL302613A (es)
MX (1) MX2020002667A (es)
PE (1) PE20212205A1 (es)
PH (1) PH12020500474A1 (es)
SG (1) SG11202002089RA (es)
TW (2) TWI823811B (es)
WO (1) WO2019051102A2 (es)
ZA (1) ZA202002325B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020004543A2 (pt) 2017-09-08 2020-09-08 Maverick Therapeutics, Inc. proteínas de ligação ativadas condicionalmente restritas
AU2019288484A1 (en) 2018-06-22 2021-01-21 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof
EP3833444A1 (en) 2018-08-09 2021-06-16 Maverick Therapeutics, Inc. Coexpression and purification method of conditionally activated binding proteins
EP3934762A1 (en) 2019-03-05 2022-01-12 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
JP2022524337A (ja) * 2019-03-05 2022-05-02 武田薬品工業株式会社 腫瘍抗原を標的とするｆｃ領域及び部分を含有する条件的に活性化された結合タンパク質
CN114450022A (zh) * 2019-05-14 2022-05-06 狼人治疗公司 分离部分及其使用方法
EP4090686A4 (en) * 2020-01-17 2024-03-27 Immune Targeting Inc PRO-ANTIBODY REDUCING OFF-TARGET TOXICITY
JP7483896B2 (ja) * 2020-01-17 2024-05-15 エショー バイオセラピー， インク． オフターゲット毒性を低下させるプロ抗体
EP4178982A1 (en) * 2020-07-13 2023-05-17 Precirix N.V. Antibody fragment against folr1
CA3191431A1 (en) 2020-08-17 2022-02-24 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
WO2022051647A2 (en) * 2020-09-04 2022-03-10 Maverick Therapeutics, Inc. Constrained conditionally activated binding protein constructs with human serum albumin domains
JP2023552812A (ja) 2020-12-09 2023-12-19 ジャナックス セラピューティクス，インク． Ｐｓｍａおよびエフェクタ細胞抗原を標的とする腫瘍活性化抗体に関連する組成物ならびに方法
JP2023552865A (ja) 2020-12-14 2023-12-19 武田薬品工業株式会社 条件付き二重特異性結合タンパク質
WO2022212668A1 (en) * 2021-03-31 2022-10-06 Heat Biologics, Inc. Methods and compositions related to tnfrsf25/dr3 agonists
BR112023020437A2 (pt) * 2021-04-06 2024-04-30 Takeda Pharmaceuticals Co Métodos terapêuticos usando proteínas de ligação ativadas condicionalmente restritas
TW202342521A (zh) * 2022-02-23 2023-11-01 日商武田藥品工業股份有限公司 條件性雙特異性結合蛋白
WO2023212662A2 (en) * 2022-04-28 2023-11-02 Oregon Health & Science University Compositions and methods for modulating antigen binding activity

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
AU680459B2 (en) 1992-12-03 1997-07-31 Genzyme Corporation Gene therapy for cystic fibrosis
CN1263864C (zh) 1993-10-25 2006-07-12 坎吉公司 重组腺病毒载体及其使用方法
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
KR100508289B1 (ko) 1998-04-21 2005-08-17 마이크로메트 에이지 Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
ATE303445T1 (de) 1999-10-04 2005-09-15 Medicago Inc Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
ATE545703T1 (de) 2000-07-25 2012-03-15 Immunomedics Inc Multivalentes zielbindendes protein
EP1354600A1 (en) 2002-04-19 2003-10-22 Affimed Therapeutics AG Antibody combination useful for tumor therapy
DE10231109A1 (de) 2002-07-10 2004-01-22 Daimlerchrysler Ag Abgasturbine
AU2003265866A1 (en) 2002-09-03 2004-03-29 Vit Lauermann Targeted release
US20100003253A1 (en) 2002-11-08 2010-01-07 Ablynx N.V. Single domain antibodies directed against epidermal growth factor receptor and uses therefor
WO2004106381A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
ATE493441T1 (de) 2003-10-16 2011-01-15 Micromet Ag Multispezifische deimmunisierte cd3-bindende moleküle
CA2624781A1 (en) * 2005-10-11 2007-04-19 Ablynx N.V. Nanobodies tm and polypeptides against egfr and igf-ir
US20090252681A1 (en) 2005-10-11 2009-10-08 Ablynx N.V. Nanobodies and Polypeptides Against EGFR and IGF-IR
AU2006327175A1 (en) 2005-12-21 2007-06-28 Medimmune, Llc Epha2 bite molecules and uses thereof
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
SI2155783T1 (sl) 2007-04-03 2013-10-30 Amgen Research (Munich) Gmbh Medvrstno specifiäśna cd3-epsilon vezavna domena
ES2628395T3 (es) * 2007-08-15 2017-08-02 Bayer Pharma Aktiengesellschaft Anticuerpo regulado por proteasa
JP5851842B2 (ja) 2009-01-12 2016-02-03 サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. 改変した抗体組成物、それを作製および使用する方法
BRPI1012193A2 (pt) 2009-05-01 2019-09-24 Abbott Lab imunoglobulinas de domínio variável duplo e usos das mesmas
US20110029476A1 (en) 2009-07-29 2011-02-03 Kas Kasravi Indicating relationships among text documents including a patent based on characteristics of the text documents
CN102711825A (zh) * 2009-09-18 2012-10-03 米克罗麦特股份公司 用于施用EpCAMxCD3双特异性抗体的给药方案
CN102906118B (zh) * 2010-05-20 2017-07-28 埃博灵克斯股份有限公司 与her3相关的生物材料
US9193791B2 (en) 2010-08-03 2015-11-24 City Of Hope Development of masked therapeutic antibodies to limit off-target effects
MX340556B (es) 2010-08-24 2016-07-14 Roche Glycart Ag Anticuerpos biespecificos activables.
US20120225081A1 (en) 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
DK2686020T3 (en) 2011-03-17 2017-05-01 Univ Birmingham REDIRECTED IMMUNTERY
CN107903325B (zh) 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
RS58765B1 (sr) 2011-05-21 2019-06-28 Macrogenics Inc Cd3-vezujući molekuli sposobni za vezivanje za humani i nehumani cd3
US9382305B2 (en) 2011-07-01 2016-07-05 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
CN108178800B (zh) 2011-08-17 2022-06-17 葛兰素集团有限公司 具有降低的与抗药物抗体结合的经修饰的单可变结构域抗体
AR089114A1 (es) * 2011-12-09 2014-07-30 Amgen Res Munich Gmbh PREVENCION DE LOS EFECTOS ADVERSOS CAUSADOS POR LOS ANTICUERPOS BIESPECIFICOS EpCAMxCD3
RS56773B1 (sr) 2012-01-13 2018-04-30 Univ Wuerzburg J Maximilians Dvojna bipartitna funkcionalna komplementacija izazvana antigenom
AU2013226340B2 (en) 2012-02-27 2017-06-22 Ablynx N.V. CX3CR1-binding polypeptides
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
ES2680151T3 (es) 2012-03-01 2018-09-04 Amgen Research (Munich) Gmbh Moléculas de unión de polipéptidos de larga duración
WO2013163631A2 (en) 2012-04-27 2013-10-31 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
PE20150643A1 (es) 2012-06-22 2015-05-29 Cytomx Therapeutics Inc Anticuerpos de reaccion cruzada anti-jagged 1/jagged 2 anticuerpos anti-jagged activables y metodos de uso de los mismos
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
EA201592006A1 (ru) 2013-04-19 2016-03-31 Коваген Аг Новые биспецифические связывающие молекулы с противоопухолевой активностью
CA2913732A1 (en) 2013-06-04 2014-12-11 Cytomx Therapeutics, Inc. Compositions and methods for conjugating activatable antibodies
CA2912389C (en) 2013-06-10 2020-01-28 Dana-Farber Cancer Institute, Inc. Methods and compositions for reducing immunosupression by tumor cells
EP4067383A1 (en) 2013-07-25 2022-10-05 Cytomx Therapeutics Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
AP2016009475A0 (en) 2014-03-28 2016-09-30 Xencor Inc Bispecific antibodies that bind to cd38 and cd3
CN107108738A (zh) 2014-07-25 2017-08-29 西托姆克斯治疗公司 抗cd3抗体、可活化抗cd3抗体、多特异性抗cd3抗体、多特异性可活化抗cd3抗体及其使用方法
JP6749312B2 (ja) 2014-07-31 2020-09-02 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ 最適化された種間特異的二重特異性単鎖抗体コンストラクト
BR112017003582B1 (pt) 2014-08-27 2024-01-09 Memorial Sloan Kettering Cancer Center Agente de anticorpo, uso do mesmo, composição farmacêutica e receptor de antígeno quimérico
EP4074735A1 (en) 2014-08-28 2022-10-19 BioAtla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
AU2015323313B2 (en) * 2014-09-25 2021-04-01 Amgen Inc. Protease-activatable bispecific proteins
US10273305B2 (en) * 2015-04-02 2019-04-30 Ablynx N.V. Bispecific CXCR4-CD4 polypeptides with potent anti-HIV activity
CN107709363A (zh) 2015-05-01 2018-02-16 基因泰克公司 掩蔽抗cd3抗体和使用方法
PT3292150T (pt) * 2015-05-04 2020-06-01 Cytomx Therapeutics Inc Anticorpos anti-cd166 ativáveis e os seus métodos de utilização
HUE045437T2 (hu) * 2015-05-13 2019-12-30 Ablynx Nv TCR-alfa-béta reaktivitásán alapulva T-sejtet toborzó polipeptidek
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
AU2016307955A1 (en) * 2015-08-17 2018-03-08 Macrogenics, Inc. Bispecific monovalent diabodies that are capable of binding B7-H3 and CD3, and uses thereof
EP3377301B1 (en) 2015-11-16 2020-09-30 Fuji Seal International, Inc. Method and system for forming sleeved containers
WO2017087789A1 (en) 2015-11-19 2017-05-26 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
TW201808990A (zh) * 2016-03-08 2018-03-16 馬弗瑞克療法公司 可誘導性結合蛋白和使用方法
JP7101621B2 (ja) 2016-05-20 2022-07-15 ハープーン セラピューティクス，インク． 単一ドメイン血清アルブミン結合タンパク質
KR102365977B1 (ko) 2016-05-20 2022-02-22 하푼 테라퓨틱스, 인크. 단일 쇄 가변 단편 cd3 결합 단백질
CN106632681B (zh) 2016-10-11 2017-11-14 北京东方百泰生物科技有限公司 抗egfr和抗cd3双特异抗体及其应用
WO2018071777A1 (en) 2016-10-14 2018-04-19 Harpoon Therapeutics, Inc. Innate immune cell trispecific binding proteins and methods of use
WO2018160671A1 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Targeted checkpoint inhibitors and methods of use
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
MY200973A (en) 2017-04-11 2024-01-26 Inhibrx Inc Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
BR112020004543A2 (pt) 2017-09-08 2020-09-08 Maverick Therapeutics, Inc. proteínas de ligação ativadas condicionalmente restritas
EP3679068A2 (en) 2017-09-08 2020-07-15 Maverick Therapeutics, Inc. CONDITIONALLY ACTIVATED BINDING MOIETIES CONTAINING Fc REGIONS
WO2019222282A1 (en) 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Conditionally activated binding protein comprising a sterically occluded target binding domain
BR112020023330A2 (pt) 2018-05-14 2021-04-20 Harpoon Therapeutics, Inc. porção de ligação para ativação condicional de moléculas de imunoglobulina
WO2019222278A1 (en) 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Dual binding moiety
US20210290676A1 (en) 2018-07-30 2021-09-23 University Of Southern California Improving the efficacy and safety of adoptive cellular therapies
EP3833444A1 (en) 2018-08-09 2021-06-16 Maverick Therapeutics, Inc. Coexpression and purification method of conditionally activated binding proteins
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
JP2022514262A (ja) 2018-12-17 2022-02-10 レビトープ リミテッド 双子型免疫細胞エンゲージャー
CN113260379B (zh) 2018-12-21 2022-09-02 浙江时迈药业有限公司 蛋白酶可切割的双特异性抗体及其用途
JP2022524337A (ja) 2019-03-05 2022-05-02 武田薬品工業株式会社 腫瘍抗原を標的とするｆｃ領域及び部分を含有する条件的に活性化された結合タンパク質
EP3934762A1 (en) 2019-03-05 2022-01-12 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
CN114364696A (zh) 2019-05-02 2022-04-15 总医院公司 Teac和attac免疫肿瘤学组合物和方法

Also Published As

Publication number Publication date
TW202332689A (zh) 2023-08-16
BR112020004543A2 (pt) 2020-09-08
MX2020002667A (es) 2020-08-03
US11744892B2 (en) 2023-09-05
PH12020500474A1 (en) 2021-01-25
WO2019051102A2 (en) 2019-03-14
ECSP20021323A (es) 2020-07-31
IL273119B1 (en) 2023-06-01
US11744893B2 (en) 2023-09-05
US20230414752A1 (en) 2023-12-28
CN111356700A (zh) 2020-06-30
KR20200047687A (ko) 2020-05-07
CA3075034A1 (en) 2019-03-14
IL302613A (en) 2023-07-01
TW201920244A (zh) 2019-06-01
AU2023200437A1 (en) 2023-03-02
CL2021002242A1 (es) 2022-04-29
US20220273794A1 (en) 2022-09-01
AU2018328291B2 (en) 2022-10-27
EP3679067A2 (en) 2020-07-15
AU2023200434A1 (en) 2023-03-02
SG11202002089RA (en) 2020-04-29
AU2018328291A1 (en) 2020-04-23
WO2019051102A3 (en) 2019-05-23
US20240139317A1 (en) 2024-05-02
JP2023093632A (ja) 2023-07-04
US20220273795A1 (en) 2022-09-01
JP2020537496A (ja) 2020-12-24
IL273119A (en) 2020-04-30
TWI812637B (zh) 2023-08-21
IL302614A (en) 2023-07-01
ZA202002325B (en) 2023-10-25
US11406710B2 (en) 2022-08-09
CL2020000570A1 (es) 2021-03-12
IL273119B2 (en) 2023-10-01
PE20212205A1 (es) 2021-11-18
US20190076524A1 (en) 2019-03-14
JP7268005B2 (ja) 2023-05-02
JP7490853B2 (ja) 2024-05-27
TWI823811B (zh) 2023-11-21

Similar Documents

Publication Publication Date Title
CL2021002241A1 (es) Proteínas de unión condicionalmente activadas restringidas (divisional de la solicitud no. 202000570)
CY1123977T1 (el) Anti-pd-1 και anti-lag3 αντισωματα για την θεραπεια του καρκινου
UY37829A (es) Muteínas de interleucina 21 y métodos de tratamiento
CY1123256T1 (el) Συζευγματα αντισωματος enanti-cmet δραστικης ουσιας και μεθοδοι για τη χρηση αυτων
BR112018070676A2 (pt) construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos
BR112018014615A2 (pt) composições de anticorpo para ror1 e métodos relacionados
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
PE20200006A1 (es) Nuevas moleculas de union antigeno biespecificas capaces de unirse especificamente cd40 y a fap
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
BR112019007210A2 (pt) métodos e composições para o tratamento da doença de fabry
CO2019007823A2 (es) Anticuerpo anti-cd3 y moléculas que comprenden el anticuerpo
BR112021025645A2 (pt) Degradação de proteína alvo de parp14 para uso em terapia
MX2020004712A (es) Vesiculas extracelulares modificadas geneticamente con proteinas.
ATE466079T1 (de) Nukleinsäure konstrukten, pharmazeutische kompositionen und methoden für die behandlung von krebs
BR112021025720A2 (pt) Conjugados anticorpo-fármaco de fator antitecido e métodos relacionados
ECSP23018458A (es) Proteínas de unión restringidas activadas de forma condicional
AR104484A1 (es) Anticuerpos anti-psma como agentes terapéuticos
CL2021001593A1 (es) Tubulisinas y conjugados de proteína-tubulisina
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
ECSP21044421A (es) Anticuerpos anti-pmel17 y conjugados de los mismos
CO2023002375A2 (es) Anticuerpos contra ilt2 y uso de los mismos
CY1126032T1 (el) Συζευγματα αντισωματος-φαρμακου που στοχευουν uparap
CO2023009342A2 (es) Proteínas de unión condicionalmente biespecíficas
CO2023014772A2 (es) Métodos terapéuticos que usan proteínas de unión activadas condicionalmente restringidas